AbbVie’s Skyrizi hits the spot in refractory psoriasis

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL-17 inhibitors.